Research

Washington University professor receives $3.5M grant

David H. Gutmann, director of the Neurofibromatosis Center at the Washing University School of Medicine in St. Louis, was awarded a $3.5 million grant to study NF1.

Drug shrinks pediatric neural tumors

In an early-phase clinical trial, in most cases, children with neurofibromatosis type 1 and plexiform neurofibromas responded with tumor shrinkage.

Swedish teen walks using 3D printed hip implant

Fanny Fellesen, a Swedish 16-year-old with neurofibromatosis, was told she would never walk again.

Drug shows promise with hearing loss

A drug already in use for some cancers is not only halting hearing loss in some patients, but reversing it.

New drug approved for NF2 treatment

BioXcel announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to BXCL101 for the treatment of Neurofibromatosis Type 2.

Newsletter

Sign up to receive the latest neurofibromatosis news and information in your inbox!

Subscribe

Categories

Have a story you'd like to share with the NF community? Click Here!